Literature DB >> 8075888

Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species.

M Félétou1, M Germain, C Thurieau, J L Fauchère, E Canet.   

Abstract

1. Hoe 140, a recently described bradykinin B2 antagonist, and NPC 567 from an earlier generation of bradykinin B2 antagonists, were tested in rabbit and sheep isolated blood vessels. 2. In rabbit jugular vein, a bradykinin B2 preparation, NPC 567 was an antagonist (apparent pA2: 8.67 +/- 0.16) with marked residual agonistic activity (log[EC50]: -7.29 +/- 0.13). Hoe 140 was a potent non-competitive antagonist devoid of agonistic properties (slope of the Schild plot: 2.02; estimated pA2: 9.04). 3. In rabbit aorta, a bradykinin B1 preparation, NPC 567 was a competitive antagonist (pA2: 6.32 +/- 0.13) but Hoe 140 was ineffective. The two antagonists did not show any agonistic properties in this tissue. 4. In sheep femoral artery without endothelium, bradykinin and Hoe 140 induced contractions with identical efficacy and similar potency (log[EC50]: -8.05 +/- 0.12, -7.73 +/- 0.10; maximal contraction in % of KCl [60 mM]: 59.5 +/- 15.1, 62.0 +/- 13.1; for bradykinin and Hoe 140, respectively). In contrast NPC 567 was an extremely weak agonist. The contractile responses to bradykinin and Hoe 140 were inhibited by NPC 567 (apparent pKB: 6.89 +/- 0.22 and 6.58 +/- 0.08 versus bradykinin and Hoe 140, respectively) but not by a B1 bradykinin antagonist, suggesting that the receptor involved was a bradykinin B2 receptor. 5. In sheep femoral artery with endothelium, bradykinin induced a biphasic response: an endothelium-dependent relaxation and a contraction which were both inhibited by NPC 567 (apparent pKB: 7.10 +/- 0.15) and Hoe 140 (pA2: 8.38 +/- 0.12). As bradykinin B2 receptor antagonists, Hoe 140 and NPC 567 were less potent in the sheep femoral artery than in the rabbit jugular vein. Neither Hoe 140 nor NPC 567 were agonists for the endothelial receptor.6. This study demonstrates that Hoe 140, a new bradykinin B2 receptor antagonist, is more selective and more potent than NPC 567; however, it may possess, depending on the tissue studied, marked residual agonistic properties. Furthermore, bradykinin B2 receptors are subject to important species specificity. Finally, two different bradykinin B2 receptor subtypes may coexist in the sheep femoral artery with endothelium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075888      PMCID: PMC1910339          DOI: 10.1111/j.1476-5381.1994.tb13130.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Characterization and function of bradykinin receptors in vascular endothelial cells.

Authors:  C P Sung; A J Arleth; K Shikano; B A Berkowitz
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

Review 2.  pA2 and receptor differentiation: a statistical analysis of competitive antagonism.

Authors:  R J Tallarida; A Cowan; M W Adler
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

3.  Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors.

Authors:  K M Braas; D C Manning; D C Perry; S H Snyder
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

Review 4.  Pharmacology of bradykinin and related kinins.

Authors:  D Regoli; J Barabé
Journal:  Pharmacol Rev       Date:  1980-03       Impact factor: 25.468

Review 5.  Kinin receptor subtypes.

Authors:  D Regoli; N E Rhaleb; G Drapeau; S Dion
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells.

Authors:  V B Schini; C Boulanger; D Regoli; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

7.  Identification of pre- and postsynaptic bradykinin receptor sites in the vas deferens: evidence for different structural prerequisites.

Authors:  I Llona; R Vavrek; J Stewart; J P Huidobro-Toro
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

8.  Effects of nucleotides on [3H]bradykinin binding in guinea pig: further evidence for multiple B2 receptor subtypes.

Authors:  L Seguin; P S Widdowson
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

9.  Histamine release from rat peritoneal mast cells by kinin antagonists.

Authors:  P Devillier; M Renoux; G Drapeau; D Regoli
Journal:  Eur J Pharmacol       Date:  1988-04-27       Impact factor: 4.432

10.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Authors:  F J Hock; K Wirth; U Albus; W Linz; H J Gerhards; G Wiemer; S Henke; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  16 in total

Review 1.  Analgesic targets: today and tomorrow.

Authors:  Ian W Rodger
Journal:  Inflammopharmacology       Date:  2009-06-09       Impact factor: 4.473

2.  Pharmacological and functional characterization of the guinea-pig B2 bradykinin receptor stably expressed in CHO-K1 cell line.

Authors:  C Robert; D Pruneau; J-L Paquet
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Vascular kinin B(1) and B(2) receptor-mediated effects in the rat isolated perfused kidney - differential regulations.

Authors:  K Bagaté; L Develioglu; J L Imbs; B Michel; J J Helwig; M Barthelmebs
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.

Authors:  F Tomoda; R A Lew; A I Smith; A C Madden; R G Evans
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist.

Authors:  S Drube; C Liebmann
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

6.  Bradykinin increases Na(+)-K(+) pump activity in cultured guinea-pig tracheal smooth muscle cells.

Authors:  A M Dodson; K J Rhoden
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  The role of nitric oxide in the responses of the ovine digital artery to vasoactive agents and modification of these responses by endotoxin and cytokines.

Authors:  P Pawson; J Reid; A M Nolan
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

8.  Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium.

Authors:  Bikramjit Chopra; Stacey R Barrick; Susan Meyers; Jonathan M Beckel; Mark L Zeidel; Anthony P D W Ford; William C de Groat; Lori A Birder
Journal:  J Physiol       Date:  2004-12-02       Impact factor: 5.182

9.  Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo.

Authors:  Morley D Hollenberg; Mahmoud Saifeddine; Sabrina Sandhu; Steeve Houle; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

10.  Bradykinin and changes in microvascular permeability in the hamster cheek pouch: role of nitric oxide.

Authors:  M Félétou; E Bonnardel; E Canet
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.